Inclusion Criteria:

• Must give written informed consent to participate in the study (signed and dated) and any authorizations required by law
• Clinical diagnosis of FPL plus diagnosis of type 2 diabetes mellitus, hypertriglyceridemia, and fatty liver
  • Diagnosis of FPL is based on deficiency of subcutaneous body fat in a partial fashion assessed by physical examination and low skinfold thickness in anterior thigh by caliper measurement: men (≤ 10 mm) and women (≤ 22 mm), and at least 1 of the following:
    1. Genetic diagnosis of FPL OR
    2. Family history of FPL or of similar abnormal fat distribution plus 1 Minor Criteria OR
    3. In the absence of FPL-associated genetic variant or family history, 2 Minor Criteria and BMI< 35 kg/m2
  • Diabetes not well controlled on antidiabetic therapy with HbA1c ≥ 7% to ≤ 12% at Screening
  • Hypertriglyceridemia with Fasting TG levels ≥ 500 mg/dL (≥ 5.7 mmol/L) at Screening and Qualification visit, or Fasting TG levels ≥ 200 (≥ 2.26 mmol/L) at both Screening and Qualification Visits for patients who meet the genetic or family history criteria
  • Presence of hepatosteatosis (fatty liver), as evidenced by a Screening MRI indicating a hepatic fat fraction (HFF) ≥ 6.4%.

Exclusion Criteria:

• A diagnosis of generalized lipodystrophy
• A diagnosis of acquired partial lipodystrophy
• Acute pancreatitis within 4 weeks of Screening
• History within 6 months of Screening of acute or unstable cardiac condition
• LDL-C > 130 mg/dL on maximal tolerated statin therapy
• Platelet count < lower limit of normal (LLN)
• Treatment with metreleptin within the last 3 months prior to Screening